Interleukin-6 (Il-6), soluble Il-6 receptor (sIl-6) and tumor necrosis factor alpha (TNF-alpha) serum levels in multiple myeloma (MM) at presentation and in progression;Ste+ (combining ogonek sign)żenie interleukiny-6 (Il-6), rozpuszczalnego receptora dla interleukiny-6 (sIl-6R) i czynnika martwicy nowotworów alfa (TNF-alfa) w szpiczaku mnogim nie leczonym i w progresji

Polskie Archiwum Medycyny Wewnetrznej

Volumn 99, Issue 1, 1998, Pages 30-37

  Usnarska Zubkiewicz, Lidia ^a  

^a Kat i Klinika Hematologii i C   (Poland)

Author keywords

Il 6; Multiple myeloma; Sil 6R; TNF alpha

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CYCLOPHOSPHAMIDE; HYBRID PROTEIN; INTERLEUKIN 6; INTERLEUKIN 6 INTERLEUKIN 6 RECEPTOR FUSION PROTEIN, RECOMBINANT; INTERLEUKIN 6-INTERLEUKIN 6 RECEPTOR FUSION PROTEIN, RECOMBINANT; INTERLEUKIN RECEPTOR; M 2 PROTOCOL; M-2 PROTOCOL; MELPHALAN; METHYLPREDNISOLONE; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA; VINCRISTINE;

ADULT; AGED; ARTICLE; BLOOD; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DISEASE COURSE; FEMALE; HUMAN; MALE; MIDDLE AGED; MORTALITY; MULTIPLE MYELOMA; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; FEMALE; HUMANS; INTERLEUKIN-6; KIDNEY FAILURE, CHRONIC; MALE; MELPHALAN; METHYLPREDNISOLONE; MIDDLE AGED; MULTIPLE MYELOMA; PREDNISONE; RECEPTORS, INTERLEUKIN; RECOMBINANT FUSION PROTEINS; SURVIVAL RATE; TUMOR NECROSIS FACTOR-ALPHA; VINCRISTINE;

EID: 0031610334     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Klein B., Zhang X.G., Jourdan M. i wsp.: Paracrine rather than autocrine regulation of myeloma cell growth and differentiation by interleukin-6. Blood, 1989, 73, 517.
2. Kawano M., Hirano T., Matsuda T. i wsp.: Autocrine generation and essential requirement of BSF-2/Il-6 for human multiple myeloma. Nature, 1988, 332, 83.
3. Lokhorst H.M., van Driel M., Lamme T., de Smet M., Boom S.A.: Regulation of myeloma tumor growth by bone marrow stromal cells. Vth International Workshop on Multiple Myeloma, La Baule, France, 1995, 3, 22.
4. Uchiyama H., Barut B.A., Mohrbacher A.F., Chauhan D., Anderson K.C.: Adhesion of human myeloma derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood, 1993, 82, 3712.
5. Shibayama H., Tagawa S., Hattori H., Harigaya K., Taga T.: Interleukin-6 inhibits the chemotaxis of human malignant plasma cell lines. Br. J. Haematol., 1996, 93. 534.
6. Yee C., Blondi A., Wang X.H.: A possible autocrine role for interleukin-6 in two lymphoma cell lines. Blood, 1989, 74, 708.
7. Jernberg H., Pettersson M., Kishimoto T., Nilsson K. Heterogeneity in response to interleukin-6 (Il-6), expression of Il-6 and Il-6 receptor mRNA in a panel of established human multiple myeloma cell lines. Leukemia, 1991, 5, 255.
8. Urashima M., Ogata A., Chauhan D. i wsp.: Interleukin-6 promotes multiple myeloma cell growth via phosphorylation of retinoblastoma protein. Blood, 1996, 88, 2219.
9. Juge-Morineau N., Mellerin M.P., Francois S i wsp.: High incidence of deletions but infrequent inactivation of the retinoblastoma gene in human myeloma cells. Br. J. Haemat., 1995, 91, 664.
10. Kishimoto T , Akira S., Taga T.: Interleukin-6 and its receptor - a paradigm for cytokines. Science, 1992, 258, 593.
11. Yasukawa K., Saito T., Fukunaga T. i wsp.: Purification and characterization of soluble human Il-6 receptor expressed in CHO cells. J. biol. Chem., 1090, 108, 673.
12. Mullberg J., Oberthur W., Lottspeich F i wsp.: The soluble human Il-6 receptor. Mutational characterization of the proteolytic cleavage site. J. Immunol., 1994, 152, 4958.
13. Gaillard J.P., Bataille R., Brailly H. i wsp.: Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy. Eur. J. Immunol., 1993, 23, 820.
14. Klein B., Zhang X.G., Lu Zhao-Yang, Bataille R.: Interleukin-6 in human multiple myeloma. Blood, 1995, 85, 863.
15. Sawamura M., Murakami H., Tamara J., Matsushima T., Sato S., Naruse T.: Tumor necrosis factor alpha and interleukin-4 promote the differentiation of myeloma cell precursors in multiple myeloma. Br. J. Haematol., 1994, 88, 17.
16. Lichtenstein A., Berenson J., Norman D., Chans M.P., Corlile A.: Production of cytokines by bone marrow cells obtained from patients with multiple myeloma. Blood, 1989, 74, 1266.
17. Hata H., Matsuzaki H., Takatsuki K.: Autocrine growth by two cytokines, interleukin-6 and tumor necrosis factor alpha in the myeloma cell line KHM-1A, Acta Haematol. (Basel), 1990, 83, 133.
18. Durie B.C.M., Salmon S.F.: A clinical staging system for multiple myeloma. Cancer 1975, 36, 842.
19. Caligaris-Cappio F., Gregoretti M.G., Ghia P., Bergui L.: In vitro growth of human multiple myeloma: implications for biology and therapy. Hematol. Oncol. Clin. North Am., 1992, 6, 257.
20. Solary E., Guiguet M., Zeller V.: Radioimmunoassay for the measurement of serum Il-6 and its correlation with tumor cell mass parameters in multiple myeloma. Am. J. Haematol., 1992, 39, 163.
21. Nachbaur D.M., Herold M., Maneschag A., Huber H. : Serum levels in interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters. Ann. Hematol., 1991, 62, 54.
22. Kyrsonis M.C., Dedouissis G., Baxevanis C., Stamatelou M., Maniatis A.: Serum interleukin-6 (Il-6) and interleukin-4 (Il-4) in patients with multiple myeloma (MM). Br. J. Haematol., 1996, 92, 420.
23. Pelliniemi T.T., Irjala K., Mattilla K. i wsp.: Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Blood, 1995, 85, 765.
24. Pulkki K., Pelliniemi T.T., Rajamaki A., Tienhaara A., Laakso M., Lahtinen R.: Soluble interleukin-6 receptor as prognostic factor in multiple myeloma. Br. J. Haematol., 1996, 92, 370.
25. Ohtani K., Ninomiya H., Hasegawa Y.: Clinical significance of elevated soluble interleukin-6 receptor levels in the area of patients with plasma celldyscrasias. Br. J. Haematol., 1995, 91, 116.
26. Lavabre-Bertrand T., Exbrayat C., Liautard J. i wsp.: Detection of membrane and soluble interleukin-6 receptor in lymphoid malignancies. Br. J. Haematol., 1995, 91, 871.
27. Souter R., Dillon J.M., Brown D., Ralston S.H.: Cytokine expression in multiple myeloma and monoclonal gammapathy: analysis by reverse transcription/polymerase chain reaction and quantitive PCR. Leukemia Lymphoma, 1996, 24, 111.
28. Ludwig H., Nachbaur M.D., Fritz E., Krainer M., Huber: Interleukin-6 is a prognostic factor in multiple myeloma. Blood, 1991, 7, 2794.
29. Bataille R., Jourdan M., Zhang X.G., Klein B.: Scrum levels of interleukin-6, a potent myeloma growth factor, as a reflect of severity in plasma cell dyscrasias. J. Clin. Invest., 1989, 84, 2008.
30. Spicka I., Zounar R., Merta M. i wsp.: Serum levels of Il-6, TNF and their receptors in patients with myeloma kidney - possible role in pathophysiology and prediction of renal function recovery. Multiple myeloma. Advances in biology and treatment. Sept. 13-14, 1996, Vienna, Austria. Program and abstracts 62.
31. Ruef C., Budde K., Lacy J.: Interleukin-6 is an autocrine growth factor for mesangial cells. Kidney Int., 1990, 38, 249.
32. Seghal R.B.: Interleukin-6 in infection and cancer. Proc. Soc. Exp. Biol. Med., 1990. 195, 183.
33. Carter A., Merchaw S., Silvian-Draxler I., Tatarsky I.: The role of interleukin-1 and tumor necrosis factor-alpha in human multiple myeloma. Br. J. Haematol., 1990, 74, 424.
34. Ishimi Y., Miyaura C., Jin C.H. i wsp.: Il-6 is produced by osteoblast and induced bone resorption. J. Immunol., 1990, 145, 3297.
35. Alsin M., Boyce B., Devlin R.D. i wsp.: Development of an in vivo model of human multiple myeloma bone disease. Blood, 1996, 4. 1495.
36. Niesvizky R., Siegel D.S., Busquets X., Nichols G., Muindi J.: Hypercalcaemia and increased serum mterleukin-6 levels induced by all-trans retinotic acid in patients with multiple myeloma. Br. J. Haematol., 1995, 89, 217.
37. Thavasu P.W., Ganjoo R.K., Maidment S.A. i wsp.: Multiple myeloma: an immunoclinical study and response to treatment. Hematol-Oncol., 1995, 13, 69.
38. Kyrstosis M.C.H., Dedoussis G., Zervas C. i wsp.: Soluble interleukin-6 receptor (sIL-6R) a new prognostic factor in multiple myeloma. Br. J. Haematol., 1996, 93, 398.